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ABSTRACT: The COVID-19 pandemic caused by the new coronavirus (SARS-CoV-2) has become a global emergency issue for
public health. This threat has led to an acceleration in related research and, consequently, an unprecedented volume of clinical and
experimental data that include changes in gene expression resulting from infection. The SARS-CoV-2 infection database
(SARSCOVIDB: https://sarscovidb.org/) was created to mitigate the di!culties related to this scenario. The SARSCOVIDB is an
online platform that aims to integrate all di"erential gene expression data, at messenger RNA and protein levels, helping to speed up
analysis and research on the molecular impact of COVID-19. The database can be searched from di"erent experimental perspectives
and presents all related information from published data, such as viral strains, hosts, methodological approaches (proteomics or
transcriptomics), genes/proteins, and samples (clinical or experimental). All information was taken from 24 articles related to
analyses of di"erential gene expression out of 5,554 COVID-19/SARS-CoV-2-related articles published so far. The database features
12,535 genes whose expression has been identi#ed as altered due to SARS-CoV-2 infection. Thus, the SARSCOVIDB is a new
resource to support the health workers and the scienti#c community in understanding the pathogenesis and molecular impact caused
by SARS-CoV-2.
! INTRODUCTION
In December 2019, a new strain of coronavirus associated with
severe acute respiratory syndrome was identi#ed as SARS-
CoV-2.1 This is an encapsulated, single-stranded RNA virus
from the Coronaviridae family, presenting high virulence and
generating a signi#cant global impact.2 The COVID-19
pandemic caused by SARS-CoV-2 had as its epicenter the
city of Wuhan, China, and in a short time became a serious
public health problem worldwide.3 As of end-October, it is
present in more than 200 countries, accounting for 45 million
cases.4 In the USA, the country with the highest number of
deaths, more than 8 million cases and 220,000 deaths have
been recorded.4 The same dramatic outcome of the pandemic
can be noticed in Brazil, the country with the second highest
number of COVID-19 deaths, with more than 5 million cases
and 150,000 deaths.5
The increasing proliferation of SARS-CoV-2-infection cases
and the lack of speci#c therapeutics and vaccines have caused
concern among public authorities and international agencies,
resulting in the mobilization of the scienti#c community to
understand the disease and clinical outcomes aiming to
improve treatments and #nd ways to prevent COVID-19
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cases. This current scenario has generated signi#cant changes
in the #eld, such as a rapid and unprecedented increase in the
number of scienti#c articles being published. It was possible
through facilitated submission processes and preprint
publications, without peer evaluation, to disseminate articles
with very speculative results, such as computational predic-
tions.6
Understanding of the molecular aspects associated with
COVID-19 and the search for understanding the complex
response of the host after viral infection have been gaining
space.7!9 Approaches that evaluate viral infections from the
perspective of the molecular impact on the host contribute to
the understanding of the disease, which is important for
outlining potential antiviral strategies.10 Analysis of di"er-
entially expressed genes (DEGs), which allow in silico
characterization of the molecular response and the impact of
infection, can be applied. Some databases contain a collection
of expression data, but their results are mostly obtained by text
mining with automatic and semiautomatic approaches, which
may lead to nonaccurate data being deposited.11 Furthermore,
the results may present redundancy and ambiguity, and a
postanalysis is necessary for data conference.12 In the same
way, the need for bioinformaticians to extract raw data in many
of the available databases is another important limitation of its
use; it can be especially limiting for medical workers without
bioinformatics skills who are facing the COVID-19 impact in
real time and need information promptly. This scenario
hampers the access of the medical community and also other
nonspecialized scientists who may need this information in
their research. Recently, our group developed the ZIKAVID, a
database based on gathering all up-to-date gene expression
data generated after Zika virus (ZIKV) infection, containing
di"erent experimental approaches, hosts and strains, and other
related information.12
In this work, we present the SARS-CoV-2 virus infection
database (SARSCOVIDB: https://sarscovidb.org/), a public
database containing all DEGs identi#ed in SARS-CoV-2
infection and COVID-19 samples, manually developed and
Figure 1. SARSCOVID summary of contents. (A) Number of DEGs identi#ed in clinical and experimental samples; (B) number of articles
containing clinical samples; (C) number of articles containing experimental samples; (D) number of articles according to the reported origin of
SARS-CoV-2 strain; (E) number of articles according to the methodological approach.
ACS Omega http://pubs.acs.org/journal/acsodf Article
https://dx.doi.org/10.1021/acsomega.0c05701
ACS Omega 2021, 6, 3238!3243
3239
checked, with a friendly interface that is easy to navigate. This
database will help researchers worldwide, and general users, to
speed up the research and understanding of the molecular
impact of COVID-19 and possible clinical outcomes.
! RESULTS AND DISCUSSION
The outbreak of COVID-19 worldwide, linked to the lack of
e!cient treatments and approved vaccines, triggered a great
e"ort by the scienti#c community and governments toward
research involving SARS-CoV-2 and the potential comorbid-
ities associated in humans.13 For this reason, the SARSCO-
VIDB was created, comprising all data from DEGs identi#ed
after SARS-CoV-2 infection to date.
The database was initially built by searching the speci#c
terms “COVID” and “SARS-CoV-2”, with a manual double-
check for di"erential expression of genes or proteins after
SARS-CoV-2 infection, regardless of the host. To increase the
search and the user interface, all data were categorized
according to experimental approach, as described above,
including the reference article. The SARSCOVIDB is a
database to exclusively gather DEGs after SARS-CoV-2
infection and thus is an important resource to be explored
by the scienti#c community and COVID-19 medical workers
in this topic of urgent need. So far, the SARSCOVIDB
contains 12,535 di"erential DEG entries and 9,283 unique
genes. These data comprise di"erent experimental approaches
with distinct objectives, the majority being obtained from
clinical samples (Figure 1A). Thus, users can easily consult the
most frequently reported host models and compare speci#c
gene sets and other information from all published studies with
di"erential expression after SARS-CoV-2 infection. This can
facilitate the planning of new experiments, accelerating
understanding of the data available and contributing to
accelerate understanding of the molecular impact of COVID-
19. These expressive numbers in such a short time span of only
a few months also highlight the great e"orts made by the
scienti#c community to study SARS-CoV-2 infection and
COVID-19. The ZIKAVID covered the same kind of data but
on ZIKV; however, this generated a smaller number of clinical
samples of ZIKV-infected patients,12 even though the epidemic
also reached a global threat status14 and caused great concern
worldwide in 2015!2017.
Regarding the samples used, most are peripheral blood
samples (#ve serum, four blood, and two plasma samples) and
one lung sample (Figure 1B). On the other hand, the
experimental samples used di"erent cell lines, most of them
from humans (Figure 1C). As observed, many scienti#c data
have been generated using cell lines and other models but
there are still no robust animal models that faithfully replicate
the pathogenesis of SARS-CoV-2.15 Thus, the lack of
comprehensive studies comparing di"erent hosts and their
responses to infection made the survey of data gathered in the
SARSCOVIDB an important alternative to planning future
experiments regarding the choice of a more meaningful
experimental model.
The SARSCOVIDB comprises data from SARS-CoV-2
isolates from di"erent geographic regions (Figure 1D).
However, studies have still given little importance to the
impact that the mutations su"ered by strains in di"erent
regions may have on disease dynamics and virulence, as
occurred with ZIKV for instance.16 Interestingly, almost 50%
of the SARS-CoV-2 isolates or clinical samples studied are
from China, followed by America (around 16%) and Europe
(around 16%). It is important to highlight that depending on
the origin, viral isolates of SARS-CoV-2 can lead to di"erent
pathological impacts and mortality rates, as previously
suggested.17 The most recent example of a virus that had a
di"erential clinical impact, depending on the origin, was ZIKV,
where Brazilian isolates were strongly associated with severe
neurological data.18 Thus, the SARSCOVIDB contributes to
the study of the pathology on the origin of the virus, once it is
Figure 2. Database construction steps.
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possible to promptly cross-reference expression data in similar
models using viruses from di"erent sources.
Currently, there are various databases gathering genomic,
transcriptomic, and proteomic data on viruses and their impact
on the host.19,20 Several databases were developed to obtain
host!pathogen interaction data (gene expression and protein
interaction), such as VirHostNet 2.0,21 Virhostome,22 the
HIV-1 human interaction database,23 the Gene Expression
Omnibus,24 and the Virus Pathogen Resource (ViPR).19 On
SARS-CoV-2, there are already two databases: Coronascape,25
available at Metascape database, and The COVID-19 Drug and
Gene Set Library,26 which contain a collection of drug and
gene sets related to COVID-19. Although not the #rst SARS-
CoV-2 database, SARSCOVIDB is certainly the #rst to devote
itself exclusively to this speci#c focus on di"erential expression
after the SARS-CoV-2 infection. Most of the data generated by
other databases are automated by concentrating generic
information, which can result in inaccurate information.27
The SARSCOVIDB proposes to #ll this gap in a simple,
organized, and objective way by curating the data manually,
making it reliable. Furthermore, the user, who does not need a
bioinformatic background or skills, can query data from
di"erent experimental perspectives, such as the methodology
used, host, virus strain, and so forth.
! CONCLUSIONS
The SARSCOVIDB is the #rst database to gather all data to
date from di"erential expression analyses after SARS-CoV-2
infection, with manual checking of the data to give more
accurate and faster analysis. Users do not need to have a
background in bioinformatics because the user-friendly and
simple interface enables all search possibilities to be explored.
This allows the user to cross-reference data for the best
understanding and analysis of the deposited data. Finally, the
SARSCOVIDB is a promising tool for supporting scientists
and medical professionals carrying out research and analysis on
the molecular mechanisms of SARS-CoV-2 infection.
! MATERIALS AND METHODS
Original Article Selection. The SARSCOVIDB (available
at: https://sarscovidb.org/) comprises di"erential gene ex-
pression measurements, at mRNA and protein levels, built
through four main steps (Figure 2). The #rst step was a
manual search by manual text mining to #nd all articles
available in PubMed, Web of Science, Google Scholar, and
ScienceDirect databases containing the terms “SARS-CoV-2”
and “COVID-19”. Only accepted/published manuscripts were
used as the source of DEGs in SARS-CoV2 infection. This
search retrieved 5554 articles, from December 2019 to date.
The second step comprised a manual check of abstracts to
select articles containing only di"erential gene expression
measurements after SARS-CoV-2 infection. All references were
double-checked by two independent individuals, resulting in
the selection of 24 articles.
Data Collection and Related Information. The data
collected from selected papers were checked and organized,
comprising a list of DEGs at mRNA and/or protein level
identi#ed after SARS-CoV-2 infection. Other information was
also collected, such as the type of study (in vivo, in vitro, and
clinical), methodological approach (transcriptomic, proteomic,
qRT-PCR, and immunoblotting), viral strain, hosts (clinical or
animal model and cell culture), and expression status (see
Table 1). The SARSCOVIDB also contains information from
data deposited in a repository or database. The database will be
updated at least monthly by considering the availability of new
data from published articles.
Webpage Construction and User Interface. The last
step in the SARSCOVIDB was webpage development (Figure
1). MySQL v5.0, PHP v.5.2.99, and HTML10 were used to
build the database and the graphical user interface. The data
were stored and maintained by the relational database
management system (RDBMS) server, with the SQL language
used for data management. The search can be customized
easily by the user, combining speci#c proteins with hosts or
selecting a speci#c viral strain or geographic origin. The
database also provides step-by-step links to instruct the user
how to search. A list containing all genes deposited in the
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Table 1. General Information Stored in the SARSCOVIDB
SARSCOVIDB
ID
reference identi#cation of the entry in the
SARSCOVIDB.
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host/sample host model used to generate SARS-COV-2 infection data.
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